US-China ratification of Paris Agreement ramps up the pressure on Australia
Sep 05, 2016 05:49 am UTC| Insights & Views
When President Barack Obama and President Xi Jinping announced their countries ratification of the Paris climate agreement ahead of last weekends G20 meeting in Hangzhou, they boosted its chances of coming into force by...
From Southern to Sadiq Khan: everything you need to know about London's broken commuter railways
Sep 05, 2016 05:47 am UTC| Insights & Views Life
The transport secretary, Chris Grayling, has dismissed repeated calls from the mayor of London, Sadiq Khan, for Transport for London (TfL) to take over the troubled Southern Rail network, which has been hit by strikes,...

Can, or should, we save ARENA?
Sep 05, 2016 05:43 am UTC| Insights & Views Nature Politics
Once again the essential development of the renewable energy sector has been stymied by short-term, opportunistic politics. Included in the Turnbull governments omnibus savings bill is a A$1.3 billion cut in the funding...

The Climate Change Authority's gamble on political pragmatism
Sep 03, 2016 11:27 am UTC| Insights & Views Politics
The Climate Change Authoritys latest report outlining a recommended climate policy toolkit is a reflection of what is seen by many as politically feasible in Australia now. But it is piecemeal and lacks a vision for the...

Beneath the surface of tourism in Bali
Sep 03, 2016 11:21 am UTC| Insights & Views Nature
For thrill seekers and chill seekers thats the phrase the Today Tonight television program used to show areas in Bali as a freshly rebranded holiday destination, in its recent Brand New Bali series. But beneath the...
What next for British border controls in Calais?
Sep 03, 2016 11:17 am UTC| Insights & Views
During the EU referendum campaign, David Cameron suggested that Britains border control in France might not survive Brexit. Now, with an upturn in the number of irregular migrants in the Calais area, there is growing...

The logic of selling cheaper 'generics' for drug companies such as Mylan
Sep 03, 2016 11:05 am UTC| Insights & Views Business
Mylan is the latest pharmaceutical company to face controversy over its drug pricing. It has come under scrutiny and strong criticism from the public and government officials for raising the price of its EpiPen allergy...